A detailed history of Vision Point Advisory Group, LLC transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Vision Point Advisory Group, LLC holds 1,944 shares of BCLI stock, worth $660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,944
Previous 1,944 -0.0%
Holding current value
$660
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 21, 2023

BUY
$2.0 - $3.2 $3,888 - $6,220
1,944 New
1,944 $4,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $12.4M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Vision Point Advisory Group, LLC Portfolio

Follow Vision Point Advisory Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vision Point Advisory Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vision Point Advisory Group, LLC with notifications on news.